Cardiology: What You May Have Missed in 2025

Ann Intern Med. 2026 May;179(5_Supplement):e2601014. doi: 10.7326/ANNALS-26-01014. Epub 2026 Apr 14.

Abstract

During 2025, new data emerged that are important to internal medicine specialists and subspecialists who frequently encounter and manage patients with common cardiovascular conditions. Among these conditions, the landscape of therapy is changing with regard to hypertension, heart failure, and anticoagulation in atrial fibrillation. Management of acute cardiovascular diseases often involves collaboration between specialists and generalists. The choice of initial imaging modality in patients with suspected coronary artery disease, whether β-blockers are routinely indicated after myocardial infarction, and the role of invasive versus conservative management in older patients after myocardial infarction are all addressed in this article. Also reviewed are articles highlighting groundbreaking therapies in more specialized areas, such as obstructive hypertrophic cardiomyopathy and advanced treatment of hyperlipidemia. As these newer therapies become more widely disseminated, generalists will need to know about them. Finally, regarding a topic of perennial interest to many physicians and patients, an article addresses coffee drinking in patients with atrial fibrillation and suggests that it might be safer than previously believed.

Publication types

  • Review

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Anticoagulants / therapeutic use
  • Atrial Fibrillation / drug therapy
  • Atrial Fibrillation / therapy
  • Cardiology* / trends
  • Cardiovascular Diseases* / diagnosis
  • Cardiovascular Diseases* / therapy
  • Humans
  • Hyperlipidemias / drug therapy
  • Hyperlipidemias / therapy
  • Hypertension / drug therapy
  • Hypertension / therapy
  • Myocardial Infarction / drug therapy
  • Myocardial Infarction / therapy

Substances

  • Adrenergic beta-Antagonists
  • Anticoagulants